QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.054270v1 306/3/880    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patel, S. Articles by Hillard, C. J. Search for Related Content PubMed PubMed Citation Articles by Patel, S. Articles by Hillard, C. J.

NEUROPHARMACOLOGY

Differential Regulation of the Endocannabinoids Anandamide and 2-Arachidonylglycerol within the Limbic Forebrain by Dopamine Receptor Activity

Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin

Glutamatergic synaptic transmission within the striatum and prefrontal cortex regulates the neuronal synthesis of endocannabinoids. Because a primary role of dopamine is to modulate this excitatory transmission, we tested the hypothesis that dopaminergic transmission modulates endocannabinoid content in the limbic forebrain. Liquid chromatography/mass spectrometry was used to determine endogenous anandamide and 2-arachidonylglycerol (2-AG) contents within the limbic forebrain of mice after pharmacological manipulation of dopaminergic transmission. Increasing synaptic dopamine concentrations with methylphenidate significantly and dose dependently decreased both anandamide and 2-AG content. The selective dopamine reuptake inhibitor 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909) also significantly decreased anandamide and tended to decrease 2-AG content. The D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390) increased and the D1 receptor agonist 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (SKF 33939) decreased anandamide content. 2-AG content was unaffected by SCH 23390 but was significantly increased by the D2 receptor antagonist eticlopride, which had no effect on anandamide content. The D2 agonist quinpirole had a biphasic effect on anandamide content with low, autoreceptor-preferring doses increasing anandamide and higher doses decreasing it back toward control. Quinpirole did not significantly affect 2-AG content. Together, these data indicate that endogenous dopamine exerts a differential, net suppressive effect upon anandamide and 2-AG content via activation of D1 and D2 receptors, respectively. These data are consistent with the hypothesis that modulation of endocannabinoid content by dopamine is secondary to changes in glutamatergic transmission, and they provide a pharmacological framework for the rational development of endocannabinoid-based therapeutic interventions for dopamine-related neuropsychiatric disorders.

Address correspondence to: Dr. Cecilia J. Hillard, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226. E-mail: chillard{at}mcw.edu

This article has been cited by other articles:

				Q. Wang, Y. Peng, S. Chen, X. Gou, B. Hu, J. Du, Y. Lu, and L. Xiong Pretreatment With Electroacupuncture Induces Rapid Tolerance to Focal Cerebral Ischemia Through Regulation of Endocannabinoid System Stroke, June 1, 2009; 40(6): 2157 - 2164. [Abstract] [Full Text] [PDF]

				B. Pan, C. J. Hillard, and Q.-s. Liu D2 Dopamine Receptor Activation Facilitates Endocannabinoid-Mediated Long-Term Synaptic Depression of GABAergic Synaptic Transmission in Midbrain Dopamine Neurons via cAMP-Protein Kinase A Signaling J. Neurosci., December 24, 2008; 28(52): 14018 - 14030. [Abstract] [Full Text] [PDF]

				B. Pan, C. J. Hillard, and Q.-s. Liu Endocannabinoid Signaling Mediates Cocaine-Induced Inhibitory Synaptic Plasticity in Midbrain Dopamine Neurons J. Neurosci., February 6, 2008; 28(6): 1385 - 1397. [Abstract] [Full Text] [PDF]

				A.-G. Corbille, E. Valjent, G. Marsicano, C. Ledent, B. Lutz, D. Herve, and J.-A. Girault Role of Cannabinoid Type 1 Receptors in Locomotor Activity and Striatal Signaling in Response to Psychostimulants J. Neurosci., June 27, 2007; 27(26): 6937 - 6947. [Abstract] [Full Text] [PDF]

				H. Wahn, J. Wolf, F. Kram, S. Frantz, and J. A. Wagner The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2491 - H2496. [Abstract] [Full Text] [PDF]

				D. J. Rademacher, S. Patel, W.-S. V. Ho, A. M. Savoie, N. J. Rusch, K. M. Gauthier, and C. J. Hillard U-46619 but not serotonin increases endocannabinoid content in middle cerebral artery: evidence for functional relevance Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2694 - H2701. [Abstract] [Full Text] [PDF]

				S. Patel, C. T. Roelke, D. J. Rademacher, W. E. Cullinan, and C. J. Hillard Endocannabinoid Signaling Negatively Modulates Stress-Induced Activation of the Hypothalamic-Pituitary-Adrenal Axis Endocrinology, December 1, 2004; 145(12): 5431 - 5438. [Abstract] [Full Text] [PDF]

				L. Fourgeaud, S. Mato, D. Bouchet, A. Hemar, P. F. Worley, and O. J. Manzoni A Single In Vivo Exposure to Cocaine Abolishes Endocannabinoid-Mediated Long-Term Depression in the Nucleus Accumbens J. Neurosci., August 4, 2004; 24(31): 6939 - 6945. [Abstract] [Full Text] [PDF]

				J. L. Seagard, C. Dean, S. Patel, D. J. Rademacher, F. A. Hopp, W. T. Schmeling, and C. J. Hillard Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H992 - H1000. [Abstract] [Full Text] [PDF]